{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:43:19Z","timestamp":1790649799623,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-17-1-0429"],"award-info":[{"award-number":["W81XWH-17-1-0429"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vascular malformations in hereditary hemorrhagic telangiectasia (HHT) lead to chronic recurrent bleeding, hemorrhage, stroke, heart failure, and liver disease. There is great interest in identifying novel therapies for epistaxis in HHT given its associated morbidity and impact on quality of life. We aimed to measure the effectiveness of oral doxycycline for the treatment of epistaxis and explore mechanisms of action on angiogenic, inflammatory and pathway markers in HHT using a randomized controlled trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>13 HHT patients with epistaxis were recruited from the Toronto HHT Center at St. Michael\u2019s Hospital. Recruitment was stopped early due to COVID-19-related limitations. The study duration was 24\u00a0months. Patients were randomly assigned to the treatment-first or placebo-first study arm. We compared the change in weekly epistaxis duration and frequency, biomarkers, blood measurements, and intravenous iron infusion and blood transfusion requirements between treatment and placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was no significant difference in the change in weekly epistaxis duration (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.136) or frequency (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.261) between treatment and placebo. There was no significant difference in the levels of MMP-9, VEGF, ANG-2, IL-6 or ENG with treatment. Hemoglobin levels were significantly higher (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0499) during treatment. Ferritin levels were not significantly different between treatment and placebo. There was no significant difference in RBC transfusions between treatment periods (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.299).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall, our study did not demonstrate effectiveness of doxycycline as a treatment for epistaxis in patients with HHT, though the study was underpowered. Secondary analyses provided new observations which may help guide future trials in HHT.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial Registration<\/jats:italic>\n                      ClinicalTrials.gov, NCT03397004. Registered 11 January 2018 \u2013 Prospectively registered,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03397004\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03397004<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-022-02539-8","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T12:07:02Z","timestamp":1667822822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Randomized, double-blind, placebo-controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasia"],"prefix":"10.1186","volume":"17","author":[{"given":"K. P.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Chandakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Marambaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. T.","family":"Vozoris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"Marchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3746-383X","authenticated-orcid":false,"given":"M. E.","family":"Faughnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"2539_CR1","doi-asserted-by":"publisher","first-page":"989","DOI":"10.7326\/M20-1443","volume":"173","author":"ME Faughnan","year":"2020","unstructured":"Faughnan ME, Mager JJ, Hetts SW, Palda VA, Lang-Robertson K, Buscarini E, Deslandres E, Kasthuri RS, Lausman A, Poetker D, Ratjen F, Chesnutt MS, Clancy M, Whitehead KJ, Al-Samkari H, Chakinala M, Conrad M, Cortes D, Crocione C, Darling J, de Gussem E, Derksen C, Dupuis-Girod S, Foy P, Geisthoff U, Gossage JR, Hammill A, Heimdal K, Henderson K, Iyer VN, Kjeldsen AD, Komiyama M, Korenblatt K, McDonald J, McMahon J, McWilliams J, Meek ME, Mei-Zahav M, Olitsky S, Palmer S, Pantalone R, Piccirillo JF, Plahn B, Porteous MEM, Post MC, Radovanovic I, Rochon PJ, Rodriguez-Lopez J, Sabba C, Serra M, Shovlin C, Sprecher D, White AJ, Winship I, Zarrabeitia R. Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. Ann Intern Med. 2020;173:989\u20131001. https:\/\/doi.org\/10.7326\/M20-1443.","journal-title":"Ann Intern Med"},{"key":"2539_CR2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/lt.21417","volume":"14","author":"A Mitchell","year":"2008","unstructured":"Mitchell A, Adams LA, MacQuillan G, Tibballs J, Vanden Driesen R, Delriviere L. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl. 2008;14:210\u20133. https:\/\/doi.org\/10.1002\/lt.21417.","journal-title":"Liver Transpl"},{"key":"2539_CR3","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00277-006-0147-8","volume":"85","author":"D Flieger","year":"2006","unstructured":"Flieger D, Hainke S, Fischbach W. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol. 2006;85:631\u20132. https:\/\/doi.org\/10.1007\/s00277-006-0147-8.","journal-title":"Ann Hematol"},{"key":"2539_CR4","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1001\/jama.2012.250","volume":"307","author":"S Dupuis-Girod","year":"2012","unstructured":"Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Roux A, Carette MF, Gilbert- Dussardier B, Hatron PY, Lacombe P, Lorcerie B, Riviere S, Corre R, Giraud S, Bailly S, Paintaud G, Ternant D, Valette PJ, Plauchu H, Faure F. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA. 2012;307:948\u201355. https:\/\/doi.org\/10.1001\/jama.2012.250.","journal-title":"JAMA"},{"key":"2539_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2500\/ar.2014.5.0091","volume":"5","author":"AB Thompson","year":"2014","unstructured":"Thompson AB, Ross DA, Berard P, Figueroa-Bodine J, Livada N, Richer SL. Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia. Allergy Rhinol. 2014;5:91\u20135. https:\/\/doi.org\/10.2500\/ar.2014.5.0091.","journal-title":"Allergy Rhinol"},{"key":"2539_CR6","doi-asserted-by":"publisher","first-page":"E641","DOI":"10.1002\/ajh.24878","volume":"92","author":"A Chavan","year":"2017","unstructured":"Chavan A, Schumann-Binarsch S, Schmuck B, Oltmer F, Geisthoff U, Hoppe F, Wirsching K, Klempnauer J, Manns M, K\u00f6hne CH. Emerging role of bevacizumab in management of patients with symptomatic hepatic involvement in hereditary hemorrhagic telangiectasia. Am J Hematol. 2017;92:E641\u20134. https:\/\/doi.org\/10.1002\/ajh.24878.","journal-title":"Am J Hematol"},{"key":"2539_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.mayocp.2017.11.013","volume":"93","author":"VN Iyer","year":"2018","unstructured":"Iyer VN, Apala DR, Pannu BS, Kotecha A, Brinjikji W, Leise MD, Kamath PS, Misra S, Begna KH, Cartin-Ceba R, DuBrock HM, Krowka MJ, O\u2019Brien EK, Pruthi RK, Schroeder DR, Swanson KL. Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia\u2013related epistaxis and gastrointestinal bleeding. Mayo Clin Proc. 2018;93:155\u201366. https:\/\/doi.org\/10.1016\/j.mayocp.2017.11.013.","journal-title":"Mayo Clin Proc"},{"key":"2539_CR8","doi-asserted-by":"publisher","first-page":"E313","DOI":"10.1002\/ajh.24367","volume":"91","author":"N Epperla","year":"2016","unstructured":"Epperla N, Kapke JT, Karafin M, Friedman KD, Foy P. Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding. Am J Hematol. 2016;91:E313\u20134. https:\/\/doi.org\/10.1002\/ajh.24367.","journal-title":"Am J Hematol"},{"key":"2539_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.4193\/Rhin18.289","volume":"57","author":"T Rosenberg","year":"2019","unstructured":"Rosenberg T, Fialla AD, Kjeldsen J, Kjeldsen AD. Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series. Rhinology. 2019;57:242\u201351. https:\/\/doi.org\/10.4193\/Rhin18.289.","journal-title":"Rhinology"},{"key":"2539_CR10","doi-asserted-by":"publisher","first-page":"e0188943","DOI":"10.1371\/journal.pone.0188943","volume":"12","author":"A Guilhem","year":"2017","unstructured":"Guilhem A, Fargeton AE, Simon AC, Duffau P, Harle JR, Lavigne C, Carette MF, Bletry O, Kaminsky P, Leguy V, Lerolle N. Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): a retrospective study of 46 patients. PLoS ONE. 2017;12:e0188943. https:\/\/doi.org\/10.1371\/journal.pone.0188943.","journal-title":"PLoS ONE"},{"key":"2539_CR11","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.3324\/haematol.2020.261859","volume":"106","author":"H Al-Samkari","year":"2021","unstructured":"Al-Samkari H, Kasthuri RS, Parambil JG, Albitar HA, Almodallal YA, V\u00e1zquez C, Serra MM, Dupuis-Girod S, Wilsen CB, McWilliams JP, Fountain EH, Gossage JR, Weiss CR, Latif MA, Issachar A, Mei-Zahav M, Meek ME, Conrad M, Rodriguez-Lopez J, Kuter DJ, Iyer VN. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-bleed study. Haematologica. 2021;106:2161\u20139. https:\/\/doi.org\/10.3324\/haematol.2020.261859.","journal-title":"Haematologica"},{"key":"2539_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/joim.12832","volume":"285","author":"H Al-Samkari","year":"2019","unstructured":"Al-Samkari H, Kritharis A, Rodriguez-Lopez JM, Kuter DJ. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. J Intern Med. 2019;285:223\u201331. https:\/\/doi.org\/10.1111\/joim.12832.","journal-title":"J Intern Med"},{"key":"2539_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-021-09807-4","author":"JG Parambil","year":"2021","unstructured":"Parambil JG, Gossage JR, McCrae KR, Woodard TD, Menon KV, Timmerman KL, Pederson DP, Sprecher DL, Al-Samkari H. Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia. Angiogenesis. 2021. https:\/\/doi.org\/10.1007\/s10456-021-09807-4.","journal-title":"Angiogenesis"},{"key":"2539_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10456-018-9646-1","volume":"22","author":"ME Faughnan","year":"2019","unstructured":"Faughnan ME, Gossage JR, Chakinala MM, Oh SP, Kasthuri R, Hughes CC, McWilliams JP, Parambil JG, Vozoris N, Donaldson J, Paul G. Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia. Angiogenesis. 2019;22:145\u201355. https:\/\/doi.org\/10.1007\/s10456-018-9646-1.","journal-title":"Angiogenesis"},{"key":"2539_CR15","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/lary.21415","volume":"121","author":"TT Karnezis","year":"2011","unstructured":"Karnezis TT, Davidson TM. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope. 2011;121:636\u20138. https:\/\/doi.org\/10.1002\/lary.21415.","journal-title":"Laryngoscope"},{"key":"2539_CR16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00405-011-1721-9","volume":"269","author":"C Rohrmeier","year":"2012","unstructured":"Rohrmeier C, Sachs HG, Kuehnel TS. A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia. Eur Arch Otorhinolaryngol. 2012;269:531\u20136. https:\/\/doi.org\/10.1007\/s00405-011-1721-9.","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"2539_CR17","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jama.2016.11387","volume":"316","author":"S Dupuis-Girod","year":"2016","unstructured":"Dupuis-Girod S, Ambrun A, Decullier E, Fargeton AE, Roux A, Breant V, Colombet B, Riviere S, Cartier C, Lacombe P, Chinet T, Blivet S, Blondel JH, Gilbert-Dussardier B, Dufour X, Michel J, Harle JR, Dessi P, Faure F. Effect of bevacizumab nasal spray on epistaxis duration in hereditary hemorrhagic telangectasia: a randomized clinical trial. JAMA. 2016;316:934\u201342. https:\/\/doi.org\/10.1001\/jama.2016.11387.","journal-title":"JAMA"},{"key":"2539_CR18","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/jama.2016.11724","volume":"316","author":"KJ Whitehead","year":"2016","unstructured":"Whitehead KJ, Sautter NB, McWilliams JP, Chakinala MM, Merlo CA, Johnson MH, James M, Everett EM, Clancy MS, Faughnan ME, Oh SP, Olitsky SE, Pyeritz RE, Gossage JR. Effect of topical intranasal therapy on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: a randomized clinical trial. JAMA. 2016;316:943\u201351. https:\/\/doi.org\/10.1001\/jama.2016.11724.","journal-title":"JAMA"},{"key":"2539_CR19","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1161\/01.STR.0000129334.05181.b6","volume":"35","author":"CZ Lee","year":"2004","unstructured":"Lee CZ, Xu B, Hashimoto T, McCulloch CE, Yang GY, Young WL. Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model. Stroke. 2004;35:1715\u20132179. https:\/\/doi.org\/10.1161\/01.STR.0000129334.05181.b6.","journal-title":"Stroke"},{"key":"2539_CR20","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1128\/AAC.47.11.3630-3633.2003","volume":"47","author":"T Krakauer","year":"2003","unstructured":"Krakauer T, Buckley M. Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrob Agents Chemother. 2003;47:3630\u20133. https:\/\/doi.org\/10.1128\/AAC.47.11.3630-3633.2003.","journal-title":"Antimicrob Agents Chemother"},{"key":"2539_CR21","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1161\/01.STR.0000061888.71524.DF","volume":"34","author":"T Hashimoto","year":"2003","unstructured":"Hashimoto T, Wen G, Lawton MT, Boudreau NJ, Bollen AW, Yang GY, Barbaro NM, Higashida RT, Dowd CF, Halbach VV, Young WL. Abnormal expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in brain arteriovenous malformations. Stroke. 2003;34:925\u201331. https:\/\/doi.org\/10.1161\/01.STR.0000061888.71524.DF.","journal-title":"Stroke"},{"key":"2539_CR22","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3171\/jns.1996.85.5.0838","volume":"85","author":"WJ Sonstein","year":"1996","unstructured":"Sonstein WJ, Kader A, Michelsen WJ, Llena JF, Hirano A, Casper D. Expression of vascular endothelial growth factor in pediatric and adult cerebral arteriovenous malformations: an immunocytochemical study. J Neurosurg. 1996;85:838\u201345. https:\/\/doi.org\/10.3171\/jns.1996.85.5.0838.","journal-title":"J Neurosurg"},{"key":"2539_CR23","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1161\/STROKEAHA.106.481515","volume":"38","author":"CZ Lee","year":"2007","unstructured":"Lee CZ, Xue Z, Zhu Y, Yang GY, Young WL. Matrix metalloproteinase-9 inhibition attenuates vascular endothelial growth factor-induced intracerebral hemorrhage. Stroke. 2007;38:2563\u20138. https:\/\/doi.org\/10.1161\/STROKEAHA.106.481515.","journal-title":"Stroke"},{"key":"2539_CR24","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10456-015-9482-5","volume":"18","author":"H Arthur","year":"2015","unstructured":"Arthur H, Geisthoff U, Gossage JR, Hughes CC, Lacombe P, Meek ME, Oh P, Roman BL, Trerotola SO, Velthuis S, Wooderchak-Donahue W. Executive summary of the 11th HHT international scientific conference. Angiogenesis. 2015;18:511\u201324. https:\/\/doi.org\/10.1007\/s10456-015-9482-5.","journal-title":"Angiogenesis"},{"key":"2539_CR25","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/jth.15662","volume":"20","author":"JP McWilliams","year":"2022","unstructured":"McWilliams JP, Majumdar S, Kim GH, Lee J, Seals K, Tangchaiburana S, Gilbert S, Duckwiler GR. North American study for the treatment of recurrent epistaxis with doxycycline: the NOSTRIL trial. J Thromb Haemost. 2022;20:1115\u201325. https:\/\/doi.org\/10.1111\/jth.15662.","journal-title":"J Thromb Haemost"},{"key":"2539_CR26","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1002\/lary.24679","volume":"124","author":"MR Purkey","year":"2014","unstructured":"Purkey MR, Seeskin Z, Chandra R. Seasonal variation and predictors of epistaxis. Laryngoscope. 2014;124:2028\u201333. https:\/\/doi.org\/10.1002\/lary.24679.","journal-title":"Laryngoscope"},{"key":"2539_CR27","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1002\/lary.23893","volume":"123","author":"BM Silva","year":"2013","unstructured":"Silva BM, Hosman AE, Devlin HL, Shovlin CL. Lifestyle and dietary influences on nosebleed severity in hereditary hemorrhagic telangiectasia. Laryngoscope. 2013;123:1092\u20139. https:\/\/doi.org\/10.1002\/lary.23893.","journal-title":"Laryngoscope"},{"key":"2539_CR28","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.jclinepi.2010.12.019","volume":"64","author":"S Gupta","year":"2011","unstructured":"Gupta S, Faughnan ME, Tomlinson GA, Bayoumi AM. A framework for applying unfamiliar trial designs in studies of rare diseases. J Clin Epidemiol. 2011;64:1085\u201394. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.12.019.","journal-title":"J Clin Epidemiol"},{"key":"2539_CR29","doi-asserted-by":"publisher","unstructured":"Kasthuri RS, Montifar M, Nelson J, Kim H, Lawton MT, Faughnan ME, Brain Vascular Malformation Consortium HHT Investigator Group. Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia. Am J Hematol. 2017;https:\/\/doi.org\/10.1002\/ajh.24832","DOI":"10.1002\/ajh.24832"},{"key":"2539_CR30","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/07315724.2008.10719709","volume":"27","author":"MA Grondin","year":"2008","unstructured":"Grondin MA, Ruivard M, Perreve A, Derumeaux-Burel H, Perthus I, Roblin J, Thiollieres F, Gerbaud L. Prevalence of iron deficiency and health-related quality of life among female students. J Am Coll Nutr. 2008;27:337\u201341. https:\/\/doi.org\/10.1080\/07315724.2008.10719709.","journal-title":"J Am Coll Nutr"},{"key":"2539_CR31","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1023\/A:1008978114650","volume":"9","author":"AJ Patterson","year":"2000","unstructured":"Patterson AJ, Brown WJ, Powers JR, Roberts DC. Iron deficiency, general health and fatigue: results from the Australian longitudinal study on women\u2019s health. Qual Life Res. 2000;9:491\u20137. https:\/\/doi.org\/10.1023\/A:1008978114650.","journal-title":"Qual Life Res"},{"key":"2539_CR32","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.ccr.2011.02.005","volume":"19","author":"R Mazzieri","year":"2011","unstructured":"Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, Politi LS, Gentner B, Brown JL, Naldini L, De Palma M. Targeting the ANG2\/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell. 2011;19:512\u201326. https:\/\/doi.org\/10.1016\/j.ccr.2011.02.005.","journal-title":"Cancer Cell"},{"key":"2539_CR33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ccr.2011.03.016","volume":"19","author":"CE Lewis","year":"2011","unstructured":"Lewis CE, Ferrara N. Multiple effects of angiopoietin-2 blockade on tumors. Cancer Cell. 2011;19:431\u20133. https:\/\/doi.org\/10.1016\/j.ccr.2011.03.016.","journal-title":"Cancer Cell"},{"key":"2539_CR34","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/jnci\/djs009","volume":"104","author":"T Holopainen","year":"2012","unstructured":"Holopainen T, Saharinen P, D\u2019Amico G, Lampinen A, Eklund L, Sormunen R, Anisimov A, Zarkada G, Lohela M, Heloter\u00e4 H, Tammela T, Benjamin LE, Yl\u00e4-Herttuala S, Leow CC, Koh GY, Alitalo K. Effects of angiopoietin-2-blocking antibody on endothelial cell\u2013cell junctions and lung metastasis. J Natl Cancer Inst. 2012;104:461\u201375. https:\/\/doi.org\/10.1093\/jnci\/djs009.","journal-title":"J Natl Cancer Inst"},{"key":"2539_CR35","doi-asserted-by":"publisher","first-page":"a006650","DOI":"10.1101\/cshperspect.a006650","volume":"2","author":"G Thurston","year":"2012","unstructured":"Thurston G, Daly C. The complex role of angiopoietin-2 in the angiopoietin\u2013tie signaling pathway. Cold Spring Harb Perspect Med. 2012;2:a006650. https:\/\/doi.org\/10.1101\/cshperspect.a006650.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2539_CR36","doi-asserted-by":"publisher","first-page":"11205","DOI":"10.1073\/pnas.172161899","volume":"99","author":"IB Lobov","year":"2002","unstructured":"Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci. 2002;99:11205\u201310. https:\/\/doi.org\/10.1073\/pnas.172161899.","journal-title":"Proc Natl Acad Sci"},{"key":"2539_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fgene.2015.00035","volume":"6","author":"DS Ardelean","year":"2015","unstructured":"Ardelean DS, Letarte M. Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia. Front Genet. 2015;6:35. https:\/\/doi.org\/10.3389\/fgene.2015.00035.","journal-title":"Front Genet"},{"key":"2539_CR38","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s10456-014-9436-3","volume":"17","author":"C Han","year":"2014","unstructured":"Han C, Choe SW, Kim YH, Acharya AP, Keselowsky BG, Sorg BS, Lee YJ, Oh SP. VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2. Angiogenesis. 2014;17:823\u201330. https:\/\/doi.org\/10.1007\/s10456-014-9436-3.","journal-title":"Angiogenesis"},{"key":"2539_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep37366","volume":"6","author":"S Ruiz","year":"2016","unstructured":"Ruiz S, Zhao H, Chandakkar P, Chatterjee PK, Papoin J, Blanc L, Metz CN, Campagne F, Marambaud P. A mouse model of hereditary hemorrhagic telangiectasia generated by transmammary-delivered immunoblocking of BMP9 and BMP10. Sci Rep. 2016;6:1\u20132. https:\/\/doi.org\/10.1038\/srep37366.","journal-title":"Sci Rep"},{"key":"2539_CR40","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1161\/CIRCULATIONAHA.118.036952","volume":"139","author":"AM Crist","year":"2019","unstructured":"Crist AM, Zhou X, Garai J, Lee AR, Thoele J, Ullmer C, Klein C, Zabaleta J, Meadows SM. Angiopoietin-2 inhibition rescues arteriovenous malformation in a Smad4 hereditary hemorrhagic telangiectasia mouse model. Circulation. 2019;139:2049\u201363. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.036952.","journal-title":"Circulation"},{"key":"2539_CR41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nm1351","volume":"12","author":"U Fiedler","year":"2006","unstructured":"Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, Gale NW, Witzenrath M, Rosseau S, Suttorp N, Sobke A, Herrmann M, Preissner KT, Vajkoczy P, Augustin HG. Angiopoietin-2 sensitizes endothelial cells to TNF-\u03b1 and has a crucial role in the induction of inflammation. Nat Med. 2006;12:235\u20139. https:\/\/doi.org\/10.1038\/nm1351.","journal-title":"Nat Med"},{"key":"2539_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cyto.2018.02.003","volume":"105","author":"EA Schuldt","year":"2018","unstructured":"Schuldt EA, Lieb W, D\u00f6rr M, Lerch MM, V\u00f6lzke H, Nauck M, Friedrich N. Circulating angiopoietin-2 and its soluble receptor Tie-2 concentrations are related to inflammatory markers in the general population. Cytokine. 2018;105:1\u20137. https:\/\/doi.org\/10.1016\/j.cyto.2018.02.003.","journal-title":"Cytokine"},{"key":"2539_CR43","doi-asserted-by":"publisher","first-page":"e491","DOI":"10.3324\/haematol.2018.200873","volume":"103","author":"J Rodr\u00edguez-Garc\u00eda","year":"2018","unstructured":"Rodr\u00edguez-Garc\u00eda J, Zarrabeitia-Puente R, Fern\u00e1ndez-Santos R, Garc\u00eda-Erce JA. Infection prevention in patients with hereditary hemorrhagic telangiectasia. Haematologica. 2018;103:e491\u20132. https:\/\/doi.org\/10.3324\/haematol.2018.200873.","journal-title":"Haematologica"},{"key":"2539_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-86913-9","volume":"11","author":"T Seki","year":"2021","unstructured":"Seki T, Yanaihara N, Shapiro JS, Saito M, Tabata J, Yokomizo R, Noguchi D, Kuroda T, Kawabata A, Suzuki J, Takahashi K. Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma. Sci Rep. 2021;11:1\u20139. https:\/\/doi.org\/10.1038\/s41598-021-86913-9.","journal-title":"Sci Rep"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02539-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02539-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02539-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T12:11:58Z","timestamp":1667823118000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02539-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2539"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02539-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,7]]},"assertion":[{"value":"3 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Research Ethics Board at St. Michael\u2019s Hospital.\u00a0Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients signed informed consent regarding publishing their de-identified data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"405"}}